Capivasertib is a pan-Akt small-molecule inhibitor of all three Akt isoforms approved for the treatment of ER/PR-positive BC that is also has either PIK3CA-mutated or Akt-altered or demonstrated PTEN-loss (Table 2) [102]. This evidence concerns the gene ESR1 and breast cancer.